Uses
Hydrocortisone Butyrate Ointment, 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
Source: US FDA prescribing information
- Presentations
- 5
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Hydrocortisone butyrate is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. It is available as lotion, ointment and cream for topical use. MedsAcross supplies Hydrocortisone butyrate for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Corticosteroid, Corticosteroid Hormone Receptor Agonists
- ATC classification
- D07AB02 Hydrocortisone butyrate · Corticosteroids for the skin, subgroup D07A, subgroup D07AB
- US FDA first approval
- 31 March 1982
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Topical
- Dosage forms
- Lotion, Ointment, Cream, Topical solution
- Identifiers
- UNII 05RMF7YPWNQ5954738
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
Hydrocortisone Butyrate Ointment, 0.1% should be applied to the affected areas as a thin layer 2 or 3 times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
Source: US FDA prescribing information
Contraindications
None.
Source: US FDA prescribing information
Warnings and precautions
General Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent corticosteroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical corticosteroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA-axis suppression by using adrenocorticotropic hormone (ACTH) stimulation tests. If HPA-axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid.
Source: US FDA prescribing information
Side effects
The following local adverse reactions are reported infrequently with topical corticosteroids but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria.
Source: US FDA prescribing information
Storage
Store at controlled temperature between 2° to 30°C (36° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
5 presentations of Hydrocortisone butyrate, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Hydrocortisone butyrate 0.1% ointmentTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone butyrate 1 mg/mL lotionTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone butyrate 0.1% creamTopicalGeneric name | — | US FDA | Available on request |
| Hydrocortisone butyrate 1 mg/mL topical solutionTopicalGeneric name | — | US FDA | Available on request |
| Evesse 1 mg/mL lotionTopical | Perfero Pharma | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 31 March 1982 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Questions and answers
Is Hydrocortisone butyrate available for export from India?
Yes, on request. MedsAcross lists 5 presentations of Hydrocortisone butyrate and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Hydrocortisone butyrate have?
The catalogue lists 1 brand names for Hydrocortisone butyrate, including Evesse.
Is Hydrocortisone butyrate approved by the US FDA?
Yes. The US FDA first approved Hydrocortisone butyrate on 31 March 1982, according to Drugs@FDA.
Does Hydrocortisone butyrate need cold chain shipping?
No listed presentation of Hydrocortisone butyrate is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Hydrocortisone butyrate in?
Hydrocortisone butyrate is classified under ATC code D07AB02 (Hydrocortisone butyrate).
References
- Hydrocortisone Butyrate prescribing information (Oceanside Pharmaceuticals). U.S. National Library of Medicine, DailyMed. Retrieved 31 December 2020
Request Hydrocortisone butyrate for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.